Evidence map›Paper›PMID 40523512›Full record

ArticlePharmacological research2025

Locomotor activity depends on β-arrestin recruitment by the dopamine D

Alexandra H Evans, Marc Ciruela-Jardí, William Rea, Bradley M Keegan, Marjorie R Levinstein, Alessandro Bonifazi, Jianjing Cao, Shelley N Jackson, Lei Shi, Nil Casajuana-Martin and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmacological research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Alexandra H EvansIntegrative Neurobiology Section, National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, Baltimore, MD, USA.
Marc Ciruela-JardíLaboratory of Molecular Neuropharmacology, Department of Biochemistry and Molecular Biomedicine, Faculty of Biology and Institute of Biomedicine, University of Barcelona, Barcelona, Spain; Laboratory of Computational Medicine, Biostatistics Unit, Faculty of Medicine, Autonomous University of Barcelona, Bellaterra, Spain.
William ReaIntegrative Neurobiology Section, National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, Baltimore, MD, USA.
Bradley M KeeganComputational Chemistry and Molecular Biophysics Section, National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, Baltimore, MD, USA; Medicinal Chemistry Section, National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, Baltimore, MD, USA.
Marjorie R LevinsteinBiobehavioral Imaging and Molecular Neuropsychopharmacology Section, National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, Baltimore, MD, USA.
Alessandro BonifaziMedicinal Chemistry Section, National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, Baltimore, MD, USA.
Jianjing CaoMedicinal Chemistry Section, National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, Baltimore, MD, USA.
Shelley N JacksonTranslational Analytical Core, National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, Baltimore, MD, USA.
Lei ShiComputational Chemistry and Molecular Biophysics Section, National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, Baltimore, MD, USA.
Nil Casajuana-MartinLaboratory of Computational Medicine, Biostatistics Unit, Faculty of Medicine, Autonomous University of Barcelona, Bellaterra, Spain.
Ning-Sheng CaiIntegrative Neurobiology Section, National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, Baltimore, MD, USA.
Vicent CasadóLaboratory of Molecular Neuropharmacology, Department of Biochemistry and Molecular Biomedicine, Faculty of Biology and Institute of Biomedicine, University of Barcelona, Barcelona, Spain.
Christopher J EarleyDepartment of Neurology and Sleep Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Amy H NewmanMedicinal Chemistry Section, National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, Baltimore, MD, USA.
Michael MichaelidesBiobehavioral Imaging and Molecular Neuropsychopharmacology Section, National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, Baltimore, MD, USA.
Leonardo PardoLaboratory of Computational Medicine, Biostatistics Unit, Faculty of Medicine, Autonomous University of Barcelona, Bellaterra, Spain.
Estefanía MorenoLaboratory of Molecular Neuropharmacology, Department of Biochemistry and Molecular Biomedicine, Faculty of Biology and Institute of Biomedicine, University of Barcelona, Barcelona, Spain. Electronic address: estefaniamoreno@ub.edu.
Sergi FerréIntegrative Neurobiology Section, National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, Baltimore, MD, USA. Electronic address: sferre@intra.nida.nih.gov.

Funding

Neurotransmitter Receptor Heteromers in the Striatal Spine ModuleZIADA000493 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI FERRE, SERGI · 2009 to 2025
$35.6M
Novel Dopamine D3 Receptor Ligands ZIADA000424 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI NEWMAN, AMY HAUCK · 2009 to 2025
$25.9M
Structural basis for the functions of dopamine receptors, neurotransmitter transporters, and sigma 1 receptorZIADA000606 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI SHI, LEI · 2015 to 2025
$20.5M
Biobehavioral Imaging and Molecular Neuropsychopharmacology of Substance Abuse MechanismsZIADA000069 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI MICHAELIDES, MICHAEL · 2016 to 2025
$18.9M
Intramural NIH HHS ZIA DA000069Intramural NIH HHS ZIA DA000424Intramural NIH HHS ZIA DA000493Intramural NIH HHS ZIA DA000606
6 · The paper itself

Abstract

Several dopaminergic compounds, including the clinically used pramipexole, are labelled as preferential dopamine D

Indexed as

beta-ArrestinsCorpus StriatumLocomotionReceptors, Dopamine D1Receptors, Dopamine D3AnimalsDopamine AgonistsHumansMaleMiceMice, Inbred C57BLReceptors, Dopamine D2beta-ArrestinsDopamine AgonistsReceptors, Dopamine D1Receptors, Dopamine D2Receptors, Dopamine D3Dopamine D(1) receptorDopamine D(3) receptorHeteromersLocomotor activityMiceStriatumβ-arrestin

Identifiers

PMID40523512
PMCPMC12303728

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.